Skip to main content
Erschienen in: Journal of Infection and Chemotherapy 4/2011

01.08.2011 | Note

In vitro susceptibility of enterococci strains isolated from urine samples to fosfomycin and other antibiotics

verfasst von: Mehmet Butcu, Seniha Senbayrak Akcay, Asuman Sengoz Inan, Sebahat Aksaray, Derya Ozturk Engin, Gulcin Calisici

Erschienen in: Journal of Infection and Chemotherapy | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Enterococci are mostly isolated from urinary tract infections (UTIs). Increasing antibiotic resistance affects the success rate in empirical treatment, thus makes antibiotic susceptibility tests important. The aim of this study was to determine the species distribution and resistance patterns of Enterococcus strains isolated from urine samples to antibacterial agents including fosfomycin in a teaching hospital, Istanbul. The identification of 100 Enterococcus strains were determined by using conventional methods and API 20 Strep (bioMerieux France). The susceptibility testing was performed by disk diffusion and Etest. The majority of isolates were E. faecalis (67%), followed by E. faecium (33%). The ratio of E. faecalis to E. faecium was 2.03/1. E. faecalis and E. faecium strains were resistant to penicillin (38.8, 93.9%), ampicillin (4.8, 84.8%), vancomycin (1.5, 18.2%), teicoplanin (1.5, 18.2%), gentamicin (13.4, 58%), ciprofloxacin (34.3, 84.8%), levofloxacin (34.3, 87.9%), norfloxacin (38.8, 84.8%), tetracycline (89.6, 48.5%), nitrofurantoin (1.5, 39.4%), and fosfomycin (2.3, 0%) (p < 0.0001), respectively. Resistance to fosfomycin was observed in neither E. faecium strains, nor vancomycine-resistant enterococci strains. It was concluded that, enterococci are important pathogens for UTI; species identification and periodic evaluation of antibiotic susceptibility pattern would be guide for early empirical treatment and in uncomplicated UTI, fosfomycin could be an alternative option for therapy.
Literatur
1.
Zurück zum Zitat Arias AC, Murray BE. Enterococcus species, Streptococcus bovis group and Leuconostoc species. In: Mandell GL, Bennet JE, Dolin R, editors. Principles and practice of ınfectious disease, vol 2, 7th ed. Amsterdam: Elsevier/Churchill Livingstone; 2010. pp. 2643–53. Arias AC, Murray BE. Enterococcus species, Streptococcus bovis group and Leuconostoc species. In: Mandell GL, Bennet JE, Dolin R, editors. Principles and practice of ınfectious disease, vol 2, 7th ed. Amsterdam: Elsevier/Churchill Livingstone; 2010. pp. 2643–53.
2.
Zurück zum Zitat Patel SS, Balfour SA, Bryson HM. Fosfomycin tromethamine: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997;53(4):637–56.PubMedCrossRef Patel SS, Balfour SA, Bryson HM. Fosfomycin tromethamine: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997;53(4):637–56.PubMedCrossRef
3.
Zurück zum Zitat Maviglia R, Nestorini R, Pennisi MA. Role of old antibiotics in multidrug resistant bacterial infections. Curr Drug Targets. 2009;10:895–905.PubMedCrossRef Maviglia R, Nestorini R, Pennisi MA. Role of old antibiotics in multidrug resistant bacterial infections. Curr Drug Targets. 2009;10:895–905.PubMedCrossRef
4.
Zurück zum Zitat Baylan O. Fosfomycin: past, present and future. Mikrobiyol Bul. 2010;44(2):311–21.PubMed Baylan O. Fosfomycin: past, present and future. Mikrobiyol Bul. 2010;44(2):311–21.PubMed
5.
Zurück zum Zitat Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. In: 19th informational supplement, M100-S18. Wayne, PA: CLSI; 2009. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. In: 19th informational supplement, M100-S18. Wayne, PA: CLSI; 2009.
6.
Zurück zum Zitat Simonsen GS, Smabrekke L, Monnet DL, Sørensen TL, Møller JK, Kristinsson KG, Lagerqvist-Widh A, et al. Prevalence of resistance to ampicillin, gentamicin and vancomycin in Enterococcus faecalis isolates from clinical specimens and use of antimicrobials in five Nordic hospitals. J Antimicrob Chemother. 2003;51(2):323–31.PubMedCrossRef Simonsen GS, Smabrekke L, Monnet DL, Sørensen TL, Møller JK, Kristinsson KG, Lagerqvist-Widh A, et al. Prevalence of resistance to ampicillin, gentamicin and vancomycin in Enterococcus faecalis isolates from clinical specimens and use of antimicrobials in five Nordic hospitals. J Antimicrob Chemother. 2003;51(2):323–31.PubMedCrossRef
7.
Zurück zum Zitat Phaller MA, Jones RN, Doern GV, Kugler K, The Sentry Participants Group. Bacterial pathogens isolates from patient with bloodstream infection: frequencies of occurences and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother. 1998;7:1762–70. Phaller MA, Jones RN, Doern GV, Kugler K, The Sentry Participants Group. Bacterial pathogens isolates from patient with bloodstream infection: frequencies of occurences and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother. 1998;7:1762–70.
8.
Zurück zum Zitat Daza R, Gutierrez J, Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents. 2001;18:211–5.PubMedCrossRef Daza R, Gutierrez J, Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents. 2001;18:211–5.PubMedCrossRef
9.
Zurück zum Zitat Kaçmaz B, Aksoy A. Antimicrobial resistance of enterococci in Turkey. Int J Antimicrob Agents. 2005;25:535–8.PubMedCrossRef Kaçmaz B, Aksoy A. Antimicrobial resistance of enterococci in Turkey. Int J Antimicrob Agents. 2005;25:535–8.PubMedCrossRef
10.
Zurück zum Zitat Quinones D, Goni P, Rubio MC, Duran E, Gómez-Lus R. Enterococcus spp. isolated from Cuba; species frequency of occurrence and antimicrobial susceptibility profile. Diagn Microbiol Infect Dis. 2005;51(1):63–7.PubMedCrossRef Quinones D, Goni P, Rubio MC, Duran E, Gómez-Lus R. Enterococcus spp. isolated from Cuba; species frequency of occurrence and antimicrobial susceptibility profile. Diagn Microbiol Infect Dis. 2005;51(1):63–7.PubMedCrossRef
11.
Zurück zum Zitat Fuchs PC, Barry AL, Brown SD. Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J Antimicrob Chemother. 1999;43(1):137–40.PubMedCrossRef Fuchs PC, Barry AL, Brown SD. Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J Antimicrob Chemother. 1999;43(1):137–40.PubMedCrossRef
12.
Zurück zum Zitat Cilli F, Pullukcu H, Aydemir S, Sipahi OR, Tasbakan M. In vitro activity of fosfomycin tromethamine and linezolid against vancomycin-resistant Enterococcus faecium isolates. Int J Antimicrob Agents. 2008;31:290–8.CrossRef Cilli F, Pullukcu H, Aydemir S, Sipahi OR, Tasbakan M. In vitro activity of fosfomycin tromethamine and linezolid against vancomycin-resistant Enterococcus faecium isolates. Int J Antimicrob Agents. 2008;31:290–8.CrossRef
13.
Zurück zum Zitat Allerberger F, Klare I. In vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother. 1999;43(2):211–7.PubMedCrossRef Allerberger F, Klare I. In vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother. 1999;43(2):211–7.PubMedCrossRef
14.
Zurück zum Zitat Perri MB, Hershberger E, Lonescu M, Lauter C, Zervos MJ. In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis. 2002;42:269–71.PubMedCrossRef Perri MB, Hershberger E, Lonescu M, Lauter C, Zervos MJ. In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis. 2002;42:269–71.PubMedCrossRef
15.
Zurück zum Zitat Shrestha NK, Chua JD, Tuohy MJ, Wilson DA, Procop GW, Longworth DL, et al. Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin. Scand J Infect Dis. 2003;35:12–4. Shrestha NK, Chua JD, Tuohy MJ, Wilson DA, Procop GW, Longworth DL, et al. Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin. Scand J Infect Dis. 2003;35:12–4.
Metadaten
Titel
In vitro susceptibility of enterococci strains isolated from urine samples to fosfomycin and other antibiotics
verfasst von
Mehmet Butcu
Seniha Senbayrak Akcay
Asuman Sengoz Inan
Sebahat Aksaray
Derya Ozturk Engin
Gulcin Calisici
Publikationsdatum
01.08.2011
Verlag
Springer Japan
Erschienen in
Journal of Infection and Chemotherapy / Ausgabe 4/2011
Print ISSN: 1341-321X
Elektronische ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-011-0212-7

Weitere Artikel der Ausgabe 4/2011

Journal of Infection and Chemotherapy 4/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.